Overview
FMH testing detects and quantifies fetal RBCs in the maternal circulation to determine whether additional RhIG is needed beyond the standard postpartum dose.
Clinical Importance
Guide RhIG dosing in RhD-negative mothers delivering RhD-positive infants
Evaluate FMH after trauma, abruption, or other sensitizing events
Specimen Requirements
- Specimen: maternal EDTA whole blood collected after delivery or suspected FMH event per protocol
- Timing: collect after the sensitizing event (e.g., postpartum) as defined by institutional RhIG/FMH pathway
- Handling: mix well; do not delay beyond kit/SOP stability for rosette, KB, or flow methods
- Identity: maternal identifiers clearly distinguished from cord/neonatal specimens
Analytical Method
A qualitative screen (rosette test) detects excess fetal D+ cells in maternal D− blood. Positive screens are quantified by Kleihauer–Betke acid elution stain or flow cytometry. Dose calculators convert % fetal cells / mL FMH into vials of RhIG per institutional formula.
Instruments Used
Automated analyzers
- Flow cytometers for fetal HbF / anti-D based FMH quantitation
- Ortho Vision / Ortho Clinical Diagnostics automated immunohematology systems
- Bio-Rad IH-1000 / IH-500 and related gel/column systems
Manual methods
- Rosette screen
- Kleihauer–Betke acid elution microscopy
Reference Values
Immunohematology interpretations follow institutional SOPs aligned with AABB Standards, ISBT terminology, and applicable CLSI / BSH guidance. Reagent lots, method (tube, gel, solid-phase), and patient history critically affect results; always verify against the performing laboratory’s current procedure and applicable standards edition.
Screen negative: FMH below screen detection (standard RhIG dose usually sufficient if indicated). Quantitation: report % fetal cells or mL fetal whole blood per validated method; RhIG dose per local nomogram.
Interpretation
Critical blood bank findings (e.g., ABO discrepancy blocking issue, positive crossmatch when blood is needed urgently, acute hemolytic transfusion reaction workup) follow institutional urgent-notification pathways. Confirm the local call list.
Critical values
- Massive FMH with hemodynamic or dosing implications; urgent clinical notification
Common Causes of Increased Results
- Large FMH; additional RhIG vials required per calculation; notify obstetrics urgently
Common Causes of Decreased Results
- Screen negative / minimal FMH; standard RhIG dose when indicated
Clinical Significance
- Postpartum RhIG dosing
- Antenatal sensitizing-event evaluation
Factors Affecting Results
Pre-analytical
- Wrong timing relative to delivery/event
- Maternal specimen mislabeled as cord blood
Analytical
- False-positive rosette with weak D mothers
- KB subjectivity vs flow cytometry precision
Post-analytical
- Arithmetic errors in RhIG vial calculation
Advantages and Limitations
Advantages
- Prevents underdosing RhIG after large FMH
Limitations
- Screen methods have limits of detection
- KB is labor-intensive and imprecise vs flow
Clinical Pearls
A positive rosette is not a dose; quantify, calculate, then issue enough RhIG.
References
Authoritative textbooks, guidelines, and reviews supporting this laboratory test reference. Verify reference intervals, critical limits, and method details against institutional protocols and current guideline editions.
Textbooks
- Cohn CS, Delaney M, Johnson ST, Katz LM, eds. Technical Manual. 21st ed. AABB; 2023.
- Fung MK, Eder AF, Spitalnik SL, Westhoff CM, eds. Technical Manual. 20th ed. AABB; 2020.
- Harmening DM. Modern Blood Banking & Transfusion Practices. 7th ed. F.A. Davis; 2019.
- McPherson RA, Pincus MR. Henry's Clinical Diagnosis and Management by Laboratory Methods. 24th ed. Elsevier; 2021.
- Bain BJ, Bates I, Laffan MA, eds. Dacie and Lewis Practical Haematology (verify current edition). Blood transfusion chapters.
CLSI and Professional Guidelines
- AABB. Standards for Blood Banks and Transfusion Services (verify current edition and institutional adoption).
- U.S. Food and Drug Administration. Code of Federal Regulations Title 21 . Blood and Blood Components (verify current institutional adoption).
- World Health Organization. Blood safety and availability / transfusion guidance (verify current WHO publication and institutional adoption).
- Clinical and Laboratory Standards Institute. Related immunohematology and specimen identity standards (verify current documents and institutional adoption).
- International Society of Blood Transfusion (ISBT). Blood group terminology and transfusion guidance (verify current ISBT publications).
- British Society for Haematology (BSH). Guidelines for blood grouping, antibody testing, and transfusion practice (verify current BSH guideline editions).
- Clinical and Laboratory Standards Institute. Immunohematology, specimen identification, and related transfusion laboratory documents (verify current CLSI editions).
WHO Publications
- World Health Organization. Blood safety, availability, and clinical transfusion guidance (verify current WHO publication).
Frequently Asked Questions
Common questions about using this Fetomaternal Hemorrhage Testing laboratory test Medical Laboratory Library reference in Medical Laboratory Science education.
What is the Fetomaternal Hemorrhage Testing laboratory test reference used for?
This Medical Laboratory Library page summarizes the clinical importance of Fetomaternal Hemorrhage Testing. Review the Clinical Importance section for why the test is ordered in laboratory medicine practice.
Where can I find Fetomaternal Hemorrhage Testing specimen requirements?
See the Specimen Requirements section on this page for specimen information related to Fetomaternal Hemorrhage Testing. Confirm collection details against your laboratory protocol.
Where are Fetomaternal Hemorrhage Testing reference values listed?
See the Reference Values section on this Laboratory Library page. Reference ranges can vary by method and population, so verify intervals with your laboratory.
How do I interpret Fetomaternal Hemorrhage Testing results?
Use the Interpretation section for laboratory interpretation framing, including increased and decreased result patterns when provided. Do not treat educational text as a patient-specific diagnosis.
What analytical method is used for Fetomaternal Hemorrhage Testing?
See the Analytical Method section for principle and method notes. Method details may differ by instrument and institutional SOP.
Are related laboratory tests linked from Fetomaternal Hemorrhage Testing?
Yes. The Related Laboratory Tests section lists connected references for continued lookup in the Medical Laboratory Library.
How can I continue learning after reading Fetomaternal Hemorrhage Testing?
Use Continue learning links on this page for related Academy lessons, medical laboratory quizzes, or laboratory case studies when available for this Blood Bank / Transfusion Medicine topic.
What are the clinical pearls for Fetomaternal Hemorrhage Testing?
See the Clinical Pearls section for concise laboratory practice notes associated with Fetomaternal Hemorrhage Testing. Apply pearls alongside institutional protocols.
Reading progress
Awards XP once after you have meaningfully reviewed this article.